ROS1 Targeted Therapies: Current Status

被引：32
作者：
Azelby, Christine M. [1 ]
Sakamoto, Mandy R. [1 ]
Bowles, Daniel W. [2 ,3 ]
机构：
[1] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA
[2] Univ Colorado, Div Med Oncol, Dept Med, Anschutz Med Campus,12801 E 17th Av, Aurora, CO 80045 USA
[3] Rocky Mt Reg VA Med Ctr, Aurora, CO 80045 USA
来源：
CURRENT ONCOLOGY REPORTS | 2021年 / 23卷 / 08期
关键词：
ROS1; Non-small cell lung cancer; Targeted therapy; Molecular drivers; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; ALK INHIBITOR; PAN-TRK; CRIZOTINIB; FUSION; ENTRECTINIB; CABOZANTINIB; REARRANGEMENT; MUTATION;
D O I：
10.1007/s11912-021-01078-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose of Review Molecular drivers are increasingly identified as therapeutic targets for non-small cell lung cancer (NSCLC). This review focuses on the role of ROS1 inhibitors in treating relapsed/metastatic ROS-1 altered (ROS1+) NSCLC. Recent Findings Four FDA-approved drugs have significant activity against ROS1+ NSCLC: crizotinib, ciritinib, lorlatinib, and entrectinib. Each drug yields an overall response rates exceeding 60% with ciritinib, lorlatinib, and entrectinib possessing intracranial activity. The drugs have manageable toxicity profiles. ROS1 alterations are rare molecular drivers of NSCLC that can be effectively treated with a variety of ROS1-targetd drugs. New agents are being identified that may treat resistance mutations.
引用
收藏
页数：9
相关论文
共 51 条
  • [1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A. -L.
    El-Khoueiry, A. B.
    Rimassa, L.
    Ryoo, B. -Y.
    Cicin, I.
    Merle, P.
    Chen, Y. H.
    Park, J. -W.
    Blanc, J. -F.
    Bolondi, L.
    Klumpen, H. -J.
    Chan, S. L.
    Zagonel, V.
    Pressiani, T.
    Ryu, M. -H.
    Venook, A. P.
    Hessel, C.
    Borgman-Hagey, A. E.
    Schwab, G.
    Kelley, R. K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) : 54 - 63
  • [2] Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases
    Ali, A.
    Goffin, J. R.
    Arnold, A.
    Ellis, P. M.
    [J]. CURRENT ONCOLOGY, 2013, 20 (04) : E300 - E306
  • [3] Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
    Ardini, Elena
    Menichincheri, Maria
    Banfi, Patrizia
    Bosotti, Roberta
    De Ponti, Cristina
    Pulci, Romana
    Ballinari, Dario
    Ciomei, Marina
    Texido, Gemma
    Degrassi, Anna
    Avanzi, Nilla
    Amboldi, Nadia
    Saccardo, Maria Beatrice
    Casero, Daniele
    Orsini, Paolo
    Bandiera, Tiziano
    Mologni, Luca
    Anderson, David
    Wei, Ge
    Harris, Jason
    Vernier, Jean-Michel
    Li, Gang
    Felder, Eduard
    Donati, Daniele
    Isacchi, Antonella
    Pesenti, Enrico
    Magnaghi, Paola
    Galvani, Arturo
    [J]. MOLECULAR CANCER THERAPEUTICS, 2016, 15 (04) : 628 - 639
  • [4] Awad MM, 2013, NEW ENGL J MED, V368, P2395, DOI [10.1056/NEJMoa1215530, 10.1056/NEJMc1309091]
  • [5] Barlesi Barlesi F F, Ann Oncol, V30 30, pII48
  • [6] EXPRESSION AND REARRANGEMENT OF THE ROS1 GENE IN HUMAN GLIOBLASTOMA CELLS
    BIRCHMEIER, C
    SHARMA, S
    WIGLER, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (24) : 9270 - 9274
  • [7] Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)
    Charest, A
    Lane, K
    McMahon, K
    Park, J
    Preisinger, E
    Conroy, H
    Housman, D
    [J]. GENES CHROMOSOMES & CANCER, 2003, 37 (01) : 58 - 71
  • [8] Cho BC, 2019, J CLIN ONCOL, V37
  • [9] ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Cho, Byoung Chul
    Kim, Dong-Wan
    Bearz, Alessandra
    Laurie, Scott A.
    McKeage, Mark
    Borra, Gloria
    Park, Keunchil
    Kim, Sang-We
    Ghosn, Marwan
    Ardizzoni, Andrea
    Maiello, Evaristo
    Greystoke, Alastair
    Yu, Richard
    Osborne, Karen
    Gu, Wen
    Scott, Jeffrey W.
    Passos, Vanessa Q.
    Lau, Yvonne Y.
    Wrona, Anna
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (09) : 1357 - 1367
  • [10] Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
    Choueiri, Toni K.
    Escudier, Bernard
    Powles, Thomas
    Tannir, Nizar M.
    Mainwaring, Paul N.
    Rini, Brian I.
    Hammers, Hans J.
    Donskov, Frede
    Roth, Bruce J.
    Peltola, Katriina
    Lee, Jae Lyun
    Heng, Daniel Y. C.
    Schmidinger, Manuela
    Agarwal, Neeraj
    Sternberg, Cora N.
    McDermott, David F.
    Aftab, Dana T.
    Hessel, Colin
    Old, Christian Scheff
    Schwab, Gisela
    Hutson, Thomas E.
    Pal, Sumanta
    Motzer, Robert J.
    [J]. LANCET ONCOLOGY, 2016, 17 (07) : 917 - 927
123456